OS Therapies (NYSEAMERICAN:OSTX) Price Target Lowered to $17.00 at Lake Street Capital

OS Therapies (NYSEAMERICAN:OSTX) had its target price lowered by analysts at Lake Street Capital from $18.00 to $17.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other research analysts have also weighed in on OSTX. Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Monday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.33.

OS Therapies Price Performance

NYSEAMERICAN OSTX traded down $0.03 during trading on Tuesday, reaching $1.69. 113,323 shares of the company’s stock were exchanged, compared to its average volume of 646,061. The business has a 50 day moving average price of $1.98 and a 200-day moving average price of $1.90. The stock has a market capitalization of $53.33 million, a P/E ratio of -2.04 and a beta of -4.10. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new position in OS Therapies in the third quarter valued at about $29,000. Mercer Global Advisors Inc. ADV acquired a new stake in OS Therapies during the third quarter worth about $40,000. Millennium Management LLC bought a new position in OS Therapies in the 3rd quarter valued at about $183,000. Virtu Financial LLC raised its position in shares of OS Therapies by 252.0% in the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after buying an additional 54,269 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of OS Therapies in the 3rd quarter valued at approximately $169,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.